Get the Stockscreener App
0.2945
4.54%
-0.0141
Plus Therapeutics Inc stock is traded at $0.2945, with a volume of 2.56M.
It is down -4.54% in the last 24 hours and up +25.95% over the past month.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
See More
Previous Close:
$0.3086
Open:
$0.3065
24h Volume:
2.56M
Relative Volume:
0.28
Market Cap:
$52.46M
Revenue:
-
Net Income/Loss:
$-12.89M
P/E Ratio:
-0.1164
EPS:
-2.53
Net Cash Flow:
$-11.95M
1W Performance:
-9.16%
1M Performance:
+25.95%
6M Performance:
-40.05%
1Y Performance:
-15.83%
1-Day Range:
$0.29
$0.3081
1-Week Range:
$0.2741
$0.3194
52-Week Range:
$0.1634
$2.3099
Plus Therapeutics Inc Stock (PSTV) Company Profile
Name
Plus Therapeutics Inc
Sector
Industry
Phone
737.255.7194
Address
4200 MARATHON BLVD., AUSTIN, TX
Compare PSTV vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
0.2941 | 55.05M | 0 | -12.89M | -11.95M | -2.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.70 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.45 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
722.13 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.03 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.37 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-03-26 | Initiated | Lake Street | Buy |
| Sep-03-25 | Upgrade | D. Boral Capital | Hold → Buy |
| Mar-17-25 | Initiated | D. Boral Capital | Buy |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
| Oct-16-20 | Initiated | Maxim Group | Buy |
Plus Therapeutics Inc Stock (PSTV) Latest News
138,897,548 Common Stock of Plus Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 28-FEB-2026. - marketscreener.com
Certain Warrants of Plus Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 28-FEB-2026. - marketscreener.com
Certain Restricted Stock Units of Plus Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 28-FEB-2026. - marketscreener.com
Lake Street Sticks to Their Buy Rating for Plus Therapeutics (PSTV) - The Globe and Mail
Plus Therapeutics (PSTV) CFO granted RSUs and stock options package - Stock Titan
PLUS Therapeutics (PSTV) CEO receives large RSU and stock option grants - Stock Titan
PLUS THERAPEUTICS, Inc.Common Stock (NQ: PSTV - The Chronicle-Journal
PSTV SEC FilingsPlus Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ - Bitget
Plus Therapeutics, Inc. Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ - marketscreener.com
Plus Therapeutics (PSTV) Gains New CPT Code for Innovation in Br - GuruFocus
Plus Therapeutics announces new Category III CPT code - marketscreener.com
Plus Therapeutics Receives AMA Approval for New CPT Code for REYOBIQ in Treatment of CNS Cancers - Quiver Quantitative
New AMA code tracks REYOBIQ therapy in aggressive brain cancers - Stock Titan
PSTV Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Value Recap: Is Plus Therapeutics Inc stock undervalued right nowWeekly Stock Summary & Short-Term Swing Trade Alerts - baoquankhu1.vn
Aug EndMonth: Is Plus Therapeutics Inc stock undervalued right nowMarket Weekly Review & Comprehensive Market Scan Reports - baoquankhu1.vn
Is Plus Therapeutics Inc. in accumulation or distribution phase2025 Retail Activity & Short-Term Trading Opportunity Alerts - mfd.ru
Plus Therapeutics Updates Executive Compensation, Approves 2025 Bonuses - The Globe and Mail
Aug Gainers: Can Plus Therapeutics Inc stock double in the next yearJuly 2025 Drop Watch & Stock Timing and Entry Methods - baoquankhu1.vn
Is Plus Therapeutics Inc. stock showing strong momentumGlobal Markets & Trade Opportunity Analysis - mfd.ru
Can Plus Therapeutics Inc. stock double in the next year2025 Retail Activity & Daily Market Momentum Tracking - mfd.ru
Aug Decliners: Can Plus Therapeutics Inc stock double in the next yearQuarterly Risk Review & Capital Efficient Trading Techniques - baoquankhu1.vn
Aug EndMonth: What is MPWRs valuation compared to sectorStock Surge & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
How Analyst Revisions Are Rewriting The Story For Plus Therapeutics (PSTV) - Yahoo Finance
Merger Talk: What is the dividend yield of Plus Therapeutics IncPortfolio Gains Summary & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Plus Therapeutics (PSTV) Gets a Buy from Lake Street - The Globe and Mail
Market Rankings: Is Plus Therapeutics Inc stock undervalued right nowBond Market & Daily Entry Point Alerts - baoquankhu1.vn
Exit Recap: What is Atlas Lithium Corporations revenue forecastJuly 2025 Movers & AI Enhanced Execution Alerts - baoquankhu1.vn
Plus Therapeutics shares climb after subsidiary secures nationwide Humana coverage - MSN
Plus Therapeutics, Inc. (PSTV) Discusses Business Update, REYOBIQ Clinical Program Progress, and Recent Financial OfferingSlideshow (NASDAQ:PSTV) 2026-01-30 - Seeking Alpha
Is Plus Therapeutics Inc. a top pick in the sectorQuarterly Risk Review & Free Technical Pattern Based Buy Signals - mfd.ru
Bond Watch: What is the cash position of LifeMD IncJuly 2025 Momentum & Weekly High Momentum Picks - baoquankhu1.vn
Published on: 2026-01-27 09:16:26 - baoquankhu1.vn
Institution Moves: Is Plus Therapeutics Inc on track to beat earningsTrade Signal Summary & Daily Entry Point Trade Alerts - baoquankhu1.vn
Price Action: Is Euroholdings Ltd. stock showing strong momentumJuly 2025 Recap & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
H.C. Wainwright lowers Plus Therapeutics stock price target on equity offering - Investing.com India
Maxim Group Maintains Plus Therapeutics(PSTV.US) With Buy Rating, Cuts Target Price to $1.5 - 富途牛牛
Plus Therapeutics secures $5.7M to support leptomeningeal metastases program - MSN
H.C. Wainwright Maintains Plus Therapeutics(PSTV.US) With Buy Rating, Cuts Target Price to $1 - 富途牛牛
Plus Therapeutics (PSTV) Sees Price Target Cut by HC Wainwright | PSTV Stock News - GuruFocus
Plus Therapeutics outlines 2026 goals for cancer treatments and diagnostics By Investing.com - Investing.com South Africa
Aug Mood: Is ABCL forming higher highs and higher lowsJuly 2025 Analyst Calls & Weekly Top Gainers Trade List - baoquankhu1.vn
Market Review: What dividend growth rate does Plus Therapeutics Inc offerWeekly Gains Summary & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Plus Therapeutics, Inc. Provides Business Update on REYOBIQ Clinical Program and U.S. CNSide Commercialization - marketscreener.com
PSTV: $15M raise funds clinical and commercial growth; CNSIDE targets break-even by 2027 - TradingView — Track All Markets
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET - Sahm
Plus Therapeutics Sets 2026 Milestones For REYOBIQ Clinical Program And CNSide Commercial Rollout - Nasdaq
Plus Therapeutics outlines 2026 goals for cancer treatments and diagnostics - Investing.com
PSTV Analyst Rating Update: Price Target Lowered to $4.00 | PSTV Stock News - GuruFocus
Plus Therapeutics Sharpens Focus on CNS Cancer Strategy - TipRanks
Plus Therapeutics Inc Stock (PSTV) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.07%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):